Celltrion Invests Additional 516.1M USD in Subsidiary Celltrion USA
- Celltrion corrects total investment in its 100% subsidiary Celltrion USA to USD 516.1M (approx. 758.9B won), finalizing second payment date on May 13, 2026
- Purpose: to fund acquisition of US raw material drug facility and operating expenses
- First tranche: USD 445.8M (Dec 18, 2025), second tranche: USD 70.3M (May 13, 2026)
- Post-acquisition ownership: 100%, representing 4.32% of Celltrion's equity
- Subsidiary (FY2024): assets 517.3B won, net income 3.64B won
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: [Correction of Description] Decision on Acquisition of Stocks and Equity Securities of Other Corporations
- Company: Celltrion (068270)
- Submission: Celltrion, Inc.
- Receipt: 05-11-2026
- Under KRX KOSPI Market Division